Supporting Information

An Efficient Approach toward Formation of Polycyclic Coumarin

Derivatives via Carbocation-initiated [4 + 2] Cycloaddition and

Atom-Economic Photo-irradiated Cyclization

Ling Chen,^[a] Yu-Ming Cui,^[a] Zheng Xu,^[a] Jian Cao, *^[a] Zhan-Jiang Zheng,^[a] and Li-Wen Xu*^[a, b]

[a] Key Laboratory of Organosilicon Chemistry and Material Technology of Ministry of Education, Hangzhou Normal University, No 1378, Wenyi West Road, Science Park of HZNU, Hangzhou 311121, People's Republic of China

[b] State Key Laboratory for Oxo Synthesis and Selective Oxidation, Lanzhou Institute of Chemical Physics (LICP), Chinese Academy of Sciences (CAS), P. R. China

Table of Contents	
General experimental procedures	S2
Synthesis of 4-vinylcoumarins 3	S2-S9
Synthesis of polycyclic coumarin derivatives 4	S9-S14
NMR spectra of new compounds	S15-S42
Fluorescent spectra of 3a and 4a	S43-S45
Frontier orbital energy (in eV) calculated at B3LYP/6-31G(d,p)	S46
level of theory	
ORTEP representation of 4a	S47

General experimental procedures

General: ¹H NMR (400 MHz) and ¹³C NMR (100 MHz) spectra were recorded on a Bruker Avance (400 MHz) spectrometer, using CDCl₃ as the solvent and TMS as internal standard; chemical shifts were quoted in parts per million and *J* values were given in hertz. High resolution mass spectrometry (HRMS) was performed on a Waters Micromass GCT instrument. Melting points were uncorrected. All solvents were dried according to standard procedures. Ynamides 2^1 and propargylic silyl ether

- $\mathbf{1}^2$ were prepared by reported methods.
- 1. X. Zhang, Y. Zhang, J. Huang, R.-P. Hsung, K. C. M. Kurtz, J. Oppenheimer, M. E.
- Petersen, I. K. Sagamanova, L. Shen and M. R. Tracey, J. Org. Chem., 2006, 71, 4170.
- 2. T. Ishikawa, S. Manabe, T. Aikawa, T. Kudo and S. Saito, Org. Lett., 2004, 6, 2361.

Typical procedure for the synthesis of 4-vinylcoumarin 3



4-(2,2-diphenylvinyl)-3-phenyl-2H-chromen-2-one 3a

A vial was charged with and ZnBr₂ (67.6 mg, 0.3 mmol), propargyl silyl ether **1b** (116.0 mg, 0.3 mmol) and ynamide **2c** (56.2 mg, 0.3 mmol) and evacuated under high vacuum and backfilled with N₂. CH₂Cl₂ (3 mL) was next added and the solution was stirred at rt. Upon reaction completion (8 h, TLC, eluent: hexane-EtOAc, 15:1), the mixture was filtered over a plug of silica gel (washed with 50 mL EtOAc), and the filtrate was concentrated. The residue was purified by flash chromatography on silica gel (eluent: hexane/ethyl acetate = 15:1) to afford **3a** (88.9 mg, 74%) as a colorless solid, mp 182-184 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.73-7.75 (m, 1H), 7.49-7.53 (m, 1H), 7.19-7.31 (m, 11H), 6.99-7.04 (m, 4H), 6.70 (s, 1H), 6.57 (d, *J* = 7.2 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 161.1, 152.8, 148.4, 148.0, 142.0, 138.5, 134.0, 131.3, 130.4, 129.5, 128.4, 128.3, 128.1, 128.0, 127.65, 127.61, 126.7, 126.5, 124.2, 120.8, 120.4, 116.8. HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₂₉H₂₁O₂, 401.1536; found

401.1537.



4-(2,2-diphenylvinyl)-6-methyl-3-phenyl-2*H*-chromen-2-one 3b

Colorless solid (141.0 mg, 68%), mp 199-201 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.42 (s, 1H), 7.05-7.22 (m, 11H), 6.87-6.94 (m, 4H), 6.60 (s, 1H), 6.46 (d, *J* = 7.6 Hz, 2H), 2.25 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 161.4, 151.0, 148.3, 148.0, 142.1, 138.6, 134.1, 133.9, 132.4, 130.5, 129.5, 128.5, 128.4, 128.3, 128.1, 128.0, 127.6, 127.5, 126.4, 126.3, 121.0, 120.1, 116.5, 21.0. HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₃₀H₂₂NaO₂, 437.1512; found 437.1517.



6-chloro-4-(2,2-diphenylvinyl)-3-phenyl-2H-chromen-2-one 3c

Yellow oil (97.8 mg, 75%). ¹H NMR (400 MHz, CDCl₃): δ 7.68 (d, J = 2.4 Hz, 1H), 7.42-7.46 (m, 1H), 7.18-7.34 (m, 10H), 7.00-7.06 (m, 4H), 6.63 (s, 1H), 6.60 (d, J = 7.2 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 160.6, 151.2, 149.2, 146.9, 141.7, 138.4, 133.5, 131.2, 130.2, 129.6, 129.4, 128.7, 128.4, 128.3, 128.1, 127.9, 127.7, 127.4, 126.1, 121.4, 119.9, 118.2. HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₂₉H₁₉ClNaO₂, 457.0966; found 457.0969.



4-(2,2-dip-tolylvinyl)-3-phenyl-2H-chromen-2-one 3d

Yellow oil (83.5 mg, 65%). ¹H NMR (400 MHz, CDCl₃): δ 7.73 (d, J = 7.6 Hz, 1H), 7.47-7.49 (m, 1H), 7.34 (d, J = 8.0 Hz, 1H), 7.10-7.23 (m, 8H), 7.01 (d, J = 7.2 Hz, 2H), 6.83 (d, J = 8.0 Hz, 2H), 6.61 (s, 1H), 6.47 (d, J = 8.0 Hz, 2H), 2.34 (s, 3H), 2.25 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 161.3, 152.8, 148.43, 148.40, 139.4, 138.4, 137.9, 135.8, 134.1, 131.3, 130.4, 129.5, 129.0, 128.6, 128.3, 127.6, 126.8, 126.3, 124.2, 120.5, 119.6, 116.7, 21.25, 21.23. HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₃₁H₂₄NaO₂, 451.1669; found 451.1666.



4-(2,2-bis(4-chlorophenyl)vinyl)-3-phenyl-2*H*-chromen-2-one 3e

Yellow oil (83.1 mg, 59%). ¹H NMR (400 MHz, CDCl₃): δ 7.70-7.72 (m, 1H), 7.53-7.55 (m, 1H), 7.38 (d, J = 8.4 Hz, 1H), 7.19-7.29 (m, 6H), 7.11 (d, J = 8.4 Hz, 2H), 6.98-7.03 (m, 4H), 6.72 (s, 1H), 6.44 (d, J = 8.4 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 160.9, 152.8, 147.2, 146.1, 139.9, 136.5, 134.8, 134.4, 133.7, 131.6, 130.6, 130.3, 129.5, 128.7, 128.4, 127.8, 127.7, 126.5, 126.3, 124.4, 121.6, 120.2, 116.9. HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₂₉H₁₈Cl₂NaO₂, 491.0576; found 491.0566.



4-(2,2-diphenylvinyl)-3-p-tolyl-2H-chromen-2-one 3f

Colorless solid (89.5 mg, 72%), mp 185-187 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.70-7.72 (m, 1H), 7.46-7.50 (m, 1H), 7.20-7.34 (m, 8H), 7.01-7.05 (m, 4H), 6.93 (d, J = 8.0 Hz, 2H), 6.70 (s, 1H), 6.62 (d, J = 7.2 Hz, 2H), 2.28 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 161.2, 152.8, 148.2, 147.5, 142.1, 138.6, 137.4, 131.1, 131.0, 130.2,

129.4, 128.38. 128.36, 128.35, 128.32, 128.1, 127.9, 126.7, 126.6, 124.1, 121.0, 120.2, 116.7, 21.3. HRMS (ESI-TOF) m/z: $[M + Na]^+$ Calcd for $C_{30}H_{22}NaO_2$, 437.1512; found 437.1513.



4-(2,2-diphenylvinyl)-3-(4-methoxyphenyl)-2H-chromen-2-one 3g

Colorless solid (107.2 mg, 83%), mp 192-194 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.72 (d, *J* = 7.2 Hz, 1H), 7.48-7.49 (m, 1H), 7.15-7.34 (m, 8H), 6.96-7.05 (m, 4H), 6.76 (d, *J* = 8.0 Hz, 2H), 6.71 (s, 1H), 6.62 (d, *J* = 8.0 Hz, 2H), 3.75 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 161.4, 159.1, 152.7, 148.1, 147.3, 142.0, 138.6, 131.7, 131.1, 129.4, 128.4, 128.3, 128.1, 127.9, 126.6, 126.3, 126.1, 124.2, 121.0, 120.4, 116.7, 113.2, 55.2. HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₃₀H₂₂O₃, 431.1642; found 431.1655.



3-(4-chlorophenyl)-4-(2,2-diphenylvinyl)-2H-chromen-2-one 3h

Colorless solid (84.1 mg, 64%), mp 207-209 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.76 (d, J = 8.0 Hz, 1H), 7.51-7.55 (m, 1H), 7.14-7.37 (m, 10H), 7.02-7.06 (m, 2H), 6.89-6.91 (m, 2H), 6.71 (s, 1H), 6.57 (d, J = 7.6 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 160.9, 152.8, 148.9, 148.2, 141.8, 138.4, 133.6, 132.4, 131.8, 131.7, 129.4, 128.7, 128.5, 128.3, 128.2, 128.1, 127.8, 126.6, 125.1, 124.4, 120.3, 116.8. HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₂₉H₁₉ClNaO₂, 457.0966; found 457.0968.



3-(4-bromophenyl)-4-(2,2-diphenylvinyl)-2H-chromen-2-one 3i

Colorless solid (85.5 mg, 59%), mp 199-201 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.75-7.77 (m, 1H), 7.52-7.54 (m, 1H), 7.20-7.37 (m, 10H), 7.03-7.07 (m, 2H), 6.84 (d, J = 8.4 Hz, 2H), 6.71 (s, 1H), 6.57 (d, J = 7.2 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 160.8, 152.8, 149.0, 148.1, 141.8, 138.3, 132.9, 132.0, 131.6, 130.8, 129.4, 128.7, 128.4, 128.33, 128.27, 128.1, 126.6, 125.1, 124.4, 121.9, 120.30, 120.27, 116.9. HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₂₉H₁₉BrNaO₂, 501.0461; found 501.0482.



4-(2,2-diphenylvinyl)-3-(4-fluorophenyl)-2H-chromen-2-one 3j

Colorless solid (87.9 mg, 70%), mp 203-205 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.76 (d, J = 8.0 Hz, 1H), 7.52-7.54 (m, 1H), 7.17-7.37 (m, 8H), 7.02-7.06 (m, 2H), 6.88-6.94 (m, 4H), 6.71 (d, J = 1.6 Hz, 1H), 6.58 (d, J = 7.6 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 162.2 (d, J = 246 Hz), 161.1, 152.8, 148.7, 148.1, 141.9, 138.4, 132.2 (d, J = 9 Hz), 131.5, 129.9 (d, J = 3 Hz), 129.4, 128.6, 128.4, 128.3, 128.2, 128.0, 126.6, 125.3, 124.4, 120.5, 120.4, 116.8, 114.6 (d, J = 21 Hz). HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₂₉H₁₉FNaO₂, 441.1261 found 441.1270.



4-(2,2-diphenylvinyl)-3-o-tolyl-2H-chromen-2-one 3k

Colorless solid (100.7 mg, 81%), mp 218-220 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.74 (d, *J* = 7.6 Hz, 1H), 7.49-7.51 (m, 1H), 7.37 (d, *J* = 8.4 Hz, 1H), 7.05-7.30 (m, 13H), 6.59-6.66 (m, 3H), 1.59 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 160.4, 153.0, 149.0, 148.4, 142.3, 138.8, 133.7, 131.4, 130.6, 130.0, 129.8, 128.4, 128.33, 128.30, 128.14, 128.09, 126.9, 126.8, 125.2, 124.3, 120.7, 120.3, 116.9, 19.3. HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₃₀H₂₃O₂, 415.1693 found 415.1685.



4-(2,2-diphenylvinyl)-6-methyl-3-(naphthalen-1-yl)-2H-chromen-2-one 3l

Colorless solid (159.6 mg, 69%), mp 202-204 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.67 (d, *J* = 6.8 Hz, 1H), 7.59 (d, *J* = 8.4 Hz, 1H), 7.45 (s, 1H), 6.40-7.31 (m, 18H), 2.27 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 161.4, 151.3, 150.2, 148.0, 142.1, 138.7, 134.1, 133.5, 132.7, 131.6, 131.3, 129.6, 128.7, 128.42, 128.38, 128.2, 128.1, 127.8, 126.7, 126.2, 125.4, 125.3, 124.9, 121.3, 120.1, 116.7, 21.0. HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₃₄H₂₄NaO₂, 487.1669 found 487.1664.



3-(2-bromophenyl)-4-(2,2-diphenylvinyl)-6-methyl-2*H*-chromen-2-one 3m

Colorless solid (81.4 mg, 55%), mp 162-164 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.44-7.45 (m, 2H), 7.11-7.24 (m, 8H), 6.94-7.01 (m, 4H), 6.10-6.66 (m, 4H), 2.27 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 160.7, 151.2, 149.8, 148.1, 142.1, 138.6, 135.1, 134.2, 132.9, 132.4, 132.1, 130.0, 129.3, 128.7, 128.5, 128.4, 128.1, 127.2, 126.7, 125.3, 123.5, 120.6, 119.7, 116.7, 21.0. HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₃₀H₂₁BrNaO₂, 515.0617 found 515.0618.



3-(3-bromophenyl)-4-(2,2-diphenylvinyl)-6-methyl-2H-chromen-2-one 3n

Colorless solid (93.2 mg, 63%), mp 175-177 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.57 (s, 1H), 7.20-7.35 (m, 9H), 7.03-7.09 (m, 3H), 6.97 (s, 1H), 6.89 (d, *J* = 7.6 Hz, 1H), 6.70 (s, 1H), 6.51 (d, *J* =7.2 Hz, 2H), 2.40 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 160.9, 150.9, 149.0, 148.7, 141.9, 138.2, 136.1, 134.3, 133.4, 132.8, 130.5, 129.4, 129.1, 128.9, 128.6, 128.5, 128.4, 128.3, 128.1, 126.3, 124.7, 121.4, 120.4, 120.2, 116.6, 21.0. HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₃₀H₂₁BrNaO₂, 515.0617 found 515.0632.



3-butyl-4-(2,2-diphenylvinyl)-2H-chromen-2-one 3o

Yellow oil (63.4 mg, 56%). ¹H NMR (400 MHz, CDCl₃): δ 7.58-7.60 (m, 1H), 7.37-7.42 (m, 6H), 7.25-7.27 (m, 1H), 7.11-7.17 (m, 4H), 7.04 (d, J = 8.0 Hz, 2H), 6.75 (s, 1H), 2.46 (t, J = 7.6 Hz, 2H), 1.12-1.55 (m, 4H), 0.86 (t, J = 7.6 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 161.7, 152.4, 148.3, 146.7, 141.9, 138.8, 130.4, 129.4, 128.6, 128.5, 128.4, 128.2, 127.0, 126.4, 123.9, 120.7, 119.9, 116.6, 29.8, 28.6, 23.0, 13.9. HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₂₇H₂₅O₂, 381.1849 found 381.1851.



3-cyclopropyl-4-(2,2-diphenylvinyl)-6-methyl-2*H*-chromen-2-one 3p

Colorless solid (53.3 mg, 47%), mp 163-165 °C. ¹H NMR (400 MHz, CDCl₃): δ

7.33-7.38 (m, 6H), 7.05-7.12 (m, 5H), 6.96 (d, J = 7.2 Hz, 2H), 6.78 (s, 1H), 2.25 (s, 3H), 1.18-1.24 (m, 1H), 1.00-1.05 (m, 1H), 0.77-0.79 (m, 1H), 0.62-0.64 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 160.8, 150.2, 148.7, 147.5, 141.9, 139.2, 133.5, 131.3, 129.4, 128.6, 128.5, 128.4, 128.3, 128.2, 126.2, 125.6, 121.1, 119.8, 116.2, 21.0, 12.1, 7.7, 7.0. HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₂₇H₂₂NaO₂, 401.1512 found 401.1517.

Typical procedure for the synthesis of polycyclic coumarin derivatives 4



12,12-diphenyl-11,12-dihydronaphtho[1,2-c]chromen-5-one 4a

A solution of **3a** (50.0 mg, 0.125 mmol) in CDCl₃ (1 mL) was irradiated using high pressure Hg lamp at rt for 12 h. The solvent was removed to give the pure product **4a** in quantitative yield as a colorless solid, mp 263-265 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.60 (d, J = 8.0 Hz, 1H), 7.78-7.80 (m, 1H), 7.37-7.47 (m, 2H), 7.18-7.27 (m, 9H), 7.03-7.06 (m, 4H), 6.85 (d, J = 8.0 Hz, 1H), 3.84 (s, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 158.8, 152.9, 147.3, 144.5, 142.8, 131.4, 130.7, 128.8, 128.3, 128.1, 128.0, 127.2, 126.9, 124.4, 123.8, 119.9, 119.3, 116.9, 51.9, 37.0. HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₂₉H₂₀NaO₂, 423.1356; found 423.1339.



9-methyl-12,12-diphenyl-11,12-dihydronaphtho[1,2-c]chromen-5-one 4b

Colorless solid (50.0 mg, 100%), mp >250 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.59 (d, J = 7.6 Hz, 1H), 7.57 (s, 1H), 7.36-7.40 (m, 1H), 7.13-7.27 (m, 9H), 7.03-7.06 (m, 4H), 6.86 (d, J = 7.6 Hz, 1H), 3.81 (s, 2H), 2.41 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 159.0, 151.1, 147.3, 144.5, 142.7, 134.0, 132.6, 130.8, 128.9, 128.8, 128.2, 128.1,

127.9, 127.2, 126.8, 123.6, 119.7, 119.0, 116.6, 51.9, 37.0, 21.2. HRMS (ESI-TOF) m/z: $[M + Na]^+$ Calcd for $C_{30}H_{22}NaO_2$, 437.1512; found 437.1516.



9-chloro-12,12-diphenyl-11,12-dihydronaphtho[1,2-c]chromen-5-one 4c

Colorless solid (50.0 mg, 100%), mp >250 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.56, (d, J = 8.0 Hz, 1H), 7.76 (d, J = 2.4 Hz, 1H), 7.34-7.43 (m, 2H), 7.19-7.30 (m, 8H), 7.02-7.04 (m, 4H), 6.85 (d, J = 7.6 Hz, 1H), 3.79 (s, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 158.2, 151.2, 146.0, 144.2, 142.9, 131.3, 130.3, 129.9, 128.9, 128.81, 128.78, 128.2, 128.1, 127.3, 127.0, 123.4, 120.9, 120.5, 118.3, 51.8, 37.0. HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₂₉H₁₉ClNaO₂, 457.0966; found 457.0968.



12,12-dip-tolyl-11,12-dihydronaphtho[1,2-c]chromen-5-one 4d

Colorless solid (50.0 mg, 100%), mp >250 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.58, (d, *J* = 8.0 Hz, 1H), 7.76 (d, *J* = 7.2 Hz, 1H), 7.21-7.44 (m, 5H), 6.99 (d, *J* = 8.4 Hz, 4H), 6.91 (d, *J* = 8.4 Hz, 4H), 6.85 (d, *J* = 7.6 Hz, 1H), 3.78 (s, 2H), 2.25 (s, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 158.9, 152.9, 147.5, 143.2, 141.6, 136.4, 131.4, 130.7, 128.8, 128.7, 128.3, 127.9, 127.1, 124.4, 123.9, 119.9, 119.4, 116.9, 51.2, 37.0, 20.9. HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₃₁H₂₄NaO₂, 451.1669; found 451.1681.



12,12-bis(4-chlorophenyl)-11,12-dihydronaphtho[1,2-c]chromen-5-one 4e

Colorless solid (50.0 mg, 100%), mp >250 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.59, (d, *J* = 7.6 Hz, 1H), 7.77 (d, *J* = 7.6 Hz, 1H), 7.27-7.51 (m, 5H), 7.19 (d, *J* = 8.4 Hz, 4H), 6.97 (d, *J* = 8.4 Hz, 4H), 6.79 (d, *J* = 7.6 Hz, 1H), 3.77 (s, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 158.6, 152.9, 146.7, 142.7, 141.7, 133.1, 131.7, 130.5, 130.1, 128.6, 128.4, 128.3, 127.7, 124.5, 123.7, 119.8, 119.0, 117.1, 51.2, 36.9. HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₂₉H₁₈Cl₂NaO₂, 491.0576; found 491.0599.



2-methyl-12,12-diphenyl-11,12-dihydronaphtho[1,2-c]chromen-5-one 4f

Colorless solid (50.0 mg, 100%), mp >250 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.50, (d, J = 8.0 Hz, 1H), 7.77-7.79 (m, 1H), 7.44-7.46 (m, 1H), 7.18-7.30 (m, 9H), 7.03-7.06 (m, 4H), 6.65 (s, 1H), 3.81 (s, 2H), 2.28 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 158.9, 152.8, 146.4, 144.6, 142.7, 138.4, 131.1, 129.5, 128.8, 128.1, 128.0, 127.9, 126.8, 124.3, 123.7, 120.0, 119.4, 116.9, 51.9, 37.1, 21.6. HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₃₀H₂₂NaO₂, 437.1512; found 437.1519.



2-methoxy-12,12-diphenyl-11,12-dihydronaphtho[**1,2-**c]chromen-5-one 4g Colorless solid (50.0 mg, 100%), mp 232-234 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.61,

(d, J = 9.2 Hz, 1H), 7.76-7.78 (m, 1H), 7.43-7.45 (m, 1H), 7.18-7.28 (m, 8H), 7.03-7.06 (m, 4H), 6.90-6.93 (m, 1H), 6.40 (d, J = 2.8 Hz, 1H), 3.82 (s, 2H), 3.73 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 159.5, 159.0, 152.6, 145.2, 144.9, 144.3, 130.9, 129.6, 128.8, 128.1, 126.9, 124.3, 123.8, 123.6, 119.8, 119.5, 116.8, 116.0, 111.1, 55.2, 52.1, 36.9. HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₃₀H₂₂NaO₃, 453.1461; found 453.1454.



2-chloro-12,12-diphenyl-11,12-dihydronaphtho[1,2-c]chromen-5-one 4h

Colorless solid (50.0 mg, 100%), mp 248-250 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.58, (d, J = 8.8 Hz, 1H), 7.78-7.80 (m, 1H), 7.49-7.50 (m, 1H), 7.20-7.30 (m, 9H), 7.01-7.04 (m, 4H), 6.83 (d, J = 2.4 Hz, 1H), 3.87 (s, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 158.6, 152.9, 147.4, 144.8, 143.7, 134.3, 131.7, 129.4, 129.2, 128.8, 128.7, 128.3, 127.4, 127.2, 124.5, 123.9, 119.10, 119.07, 117.0, 51.9, 36.9. HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₂₉H₁₉ClNaO₂, 457.0966; found 457.0986.



2-bromo-12,12-diphenyl-11,12-dihydronaphtho[1,2-c]chromen-5-one 4i

Colorless solid (50.0 mg, 100%), mp 256-258 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.42 (d, J = 8.4 Hz, 1H), 7.69-7.72 (m, 1H), 7.39-7.45 (m, 2H), 7.12-7.23 (m, 8H), 6.90-6.95 (m, 5H), 3.74 (s, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 158.6, 152.9, 147.5, 145.0, 143.7, 137.8, 131.7, 130.4, 129.6, 128.7, 128.3, 127.2, 124.5, 123.9, 122.7, 119.1, 119.0, 117.0, 51.9, 36.9. HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₂₉H₁₉BrNaO₂, 501.0461; found 501.0475.



2-fluoro-12,12-diphenyl-11,12-dihydronaphtho[1,2-c]chromen-5-one 4i

Colorless solid (50.0 mg, 100%), mp 235-237 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.61-8.65 (m, 1H), 7.76-7.79 (m, 1H), 7.45-7.46 (m, 1H), 7.02-7.23 (m, 8H), 7.02-7.04 (m, 5H), 6.56-6.59 (m, 1H), 3.83 (s, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 162.4 (d, J = 248 Hz), 158.8, 152.8, 146.7, 145.8 (d, J = 6 Hz), 143.8, 131.5, 130.2 (d, J = 8 Hz), 128.7, 128.3, 127.1, 126.9 (d, J = 3 Hz), 124.5, 123.8, 119.2, 116.9, 116.2 (d, J = 24 Hz), 113.9 (d, J = 21 Hz), 52.0, 36.7. HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₂₉H₁₉FNaO₂, 441.1261; found 441.1263.



4-methyl-12,12-diphenyl-11,12-dihydronaphtho[1,2-c]chromen-5-one 4k

Colorless solid (50.0 mg, 100%), mp >250 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.74-7.76 (m, 1H), 7.44-7.46 (m, 1H), 7.23-7.28 (m, 5H), 6.70-7.20 (m, 9H), 6.57 (d, J = 7.6 Hz, 1H), 3.82 (s, 2H), 2.41 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 157.8, 153.1, 149.9, 144.8, 136.6, 131.3, 130.33, 130.27, 128.4, 128.2, 128.1, 127.9, 126.8, 126.0, 124.1, 123.9, 121.4, 119.4, 116.8, 53.7, 37.3, 22.3. HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₃₀H₂₂NaO₂, 437.1512; found 437.1533.



3-bromo-9-methyl-12,12-diphenyl-11,12-dihydronaphtho[1,2-*c*]chromen-5-one 4n

Colorless solid (Purified by crystallization, 41.0 mg, 82%), mp >250 °C. ¹H NMR

(400 MHz, CDCl₃): δ 8.78 (d, J = 2.0 Hz, 1H), 7.58 (s, 1H), 7.36-7.39 (m, 2H), 7.17-7.31 (m, 7H), 7.02-7.04 (m, 4H), 6.73 (d, J = 8.4 Hz, 1H), 3.82 (s, 2H), 2.44 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 158.6, 151.2, 148.2, 143.9, 141.6, 134.2, 133.1, 132.6, 131.0, 130.7, 130.4, 128.7, 128.3, 127.1, 123.8, 121.5, 118.7, 118.6, 116.8, 51.6, 36.9, 21.2. HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₃₀H₂₁BrNaO₂, 515.0617; found 515.0614.

NMR spectra of new compounds

























































Figure S1. Fluorescent analysis of 4-vinylcoumarin 3a in different solvents.



Figure S2. Fluorescent spectra of the solution of 4-vinylcoumarin **3a** in acetonitrile at different concentration.



Figure S3. Fluorescent analysis of 4-vinylcoumarin 4a in different solvents.



Figure S4. Fluorescent spectra of the solution of 4-vinylcoumarin **4a** in acetonitrile at different concentration.



Figure S5. Fluorescent monitoring of transformations of 4-vinylcoumarin 3a under UV

irradiation.





Figure S6. Frontier orbital energy (in eV) calculated at B3LYP/6-31G(d,p) level of theory

Note: To obtain useful information for the better understanding of the observed fluorescence intensity of **3a** and **4a**, we performed the theoretical calculations using Gaussian 09 software package. Figure S5 gives the electron density diagrams for HOMO and LUMO orbitals of **3a** and **4a**. Interestingly, **3a** has the lower HOMO and the higher LUMO level (-5.84/-1.92 ev respectively), and **4a** has the higher HOMO and the lower LUMO level (-5.80/-2.03 ev respectively). By reference to **3a**, the reduced energy gap of **4a** predominantly derives from the decrease of LUMO level due to diminishing of conjugated 4-vinyl region. These calculation outcomes of frontier orbital energy reasonably account for the difference and spectra performance of **3a** and **4a**.

References: Frisch, M. J. et al. J. Gaussian 09, Revision C. 01. (Gaussian, Wallingford, 2010).

Figure S7. Crystal Structure of 4a.

This crystal was deposited in the Cambridge Crystallographic Data Centre and assigned as CCDC 1490150. Further information can be found in the CIF file.

